Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
(Thomson Reuters ONE) -
Addex Therapeutics /
Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's
Disease Levodopa-Induced Dyskinesia (PD-LID)
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* All key objectives achieved
* Safety and tolerability demonstrated
* Statistically significant reduction in dyskinesia severity
* Effective dose identified
Geneva, Switzerland, 21 March 2012 - Addex Therapeutics (SIX:ADXN), a leading
company pioneering allosteric modulation-based drug discovery and development,
announced today positive top line data from a Phase IIa clinical study of
dipraglurant in Parkinson's disease (PD) patients suffering from debilitating
levodopa-induced dyskinesia (LID). The data show that dipraglurant met the
primary objective of the study by exhibiting a good safety and tolerability
profile. Dipraglurant also demonstrated statistically significant reduction in
LID severity with both 50mg and 100mg doses. Dipraglurant appears to reduce
dystonia severity in addition to chorea, the two major LID components. A full
analysis of the data will be presented at a scientific forum in 2012.
Dipraglurant is an oral, small molecule allosteric modulator that inhibits
selectively the metabotropic glutamate receptor 5 (mGluR5), a Class C G-Protein
Coupled Receptor (GPCR), with potential to be used in combination with levodopa
or dopamine agonists or as a standalone treatment for PD-LID, PD-related motor
symptoms, non-motor symptoms of PD and other movement disorders.
The Coordinating Investigator of the dipraglurant study, Olivier Rascol, MD,
PhD, Professor of Clinical Pharmacology at the Toulouse University Hospital, and
one of the world's leading experts on treating Parkinson's disease commented:
"There is no drug approved for the treatment of PD-LID and dipraglurant is an
exciting new approach. The study was successful in achieving the primary
objective of good safety and tolerability. In addition, these proof of concept
data are promising and warrant further investigation of dipraglurant in
Parkinson's disease."
In this double-blind, placebo-controlled study conducted in the US and Europe,
the primary objective was to demonstrate safety and tolerability in PD-LID
patients. In addition, the trial was designed to evaluate exploratory efficacy
as a secondary objective. Efficacy was measured using the modified Abnormal
Involuntary Movement Scale (mAIMS), patient diaries documenting "off-time"
(impaired voluntary movement), "on-time" (with or without dyskinesia) and sleep.
Additional endpoints include the Unified Parkinson's Disease Rating Scale
(UPDRS), the Clinician & Patient Global Impression of Change (CGIC & PGIC), and
an evaluation of the patients' mood using the Hospital Anxiety & Depression
Score. The trial was supported by a grant from The Michael J. Fox Foundation for
Parkinson's Research.
"Dyskinesia is a top priority for our Foundation because of its significant
negative impact on patients' quality of life," said Todd Sherer, PhD, CEO of The
Michael J. Fox Foundation. "A successful treatment for PD-LID will change the
way Parkinson's disease is treated by enabling physicians to use levodopa
earlier and more effectively. To this end, since 2006, we have been funding
research on mGluR5 inhibition as one of the most promising potential treatments
for LID. We are proud to have been involved in funding this trial of
dipraglurant by Addex, which is at the forefront of this effort."
A total of 76 male and female patients (dipraglurant, n = 52; placebo, n = 24)
with moderate or severe PD-LID were randomized into the study. Patients followed
a dose-titration regimen, receiving 50mg doses from Day 1 to Day 14 and then
100mg from Day 14 until Day 28. This first-in-patients study met its primary
objective of demonstrating safety and tolerability in patients with PD. There
were no significant changes in any safety monitoring parameters and, in
particular, no changes in liver function tests were seen in either treatment
group. Both the 50mg and 100mg dose levels were well tolerated. The incidence of
adverse events was similar in both active and placebo groups (88.5% for
dipraglurant versus 75% for placebo). Typical mGluR5-type adverse events
(vertigo, visual disturbance, feeling drunk) were seen in less than 10% of
patients in the dipraglurant group but were not severe or dose limiting.
Exploratory efficacy data showed an anti-dyskinetic effect on observer evaluated
mAIMS and in patient reported diary data. Both the 50mg and 100mg doses of
dipraglurant showed a statistically significant reduction in LID. Peak mAIMS was
significantly reduced on Day 1 (50mg; p = 0.042) and on Day 14 (100mg; p =
0.038). The targeted magnitude of effect of either a 30% reduction in mAIMS or a
20% separation from placebo was achieved on Days 1, 14 and 28. The magnitude of
reduction in mAIMs was maintained for dipraglurant on Day 28 (100mg), but not
statistically significant due to an increase in placebo response on that day.
Similar results were seen for the area under the curve (AUC) mAIMS evaluation in
the total 3 hour post levodopa dosing period, with about a 30% reduction in the
dipraglurant group at Days 14 and 28, which was statistically significant at Day
14 (p = 0.042). In a subset of patients with levodopa-induced dystonia,
dipraglurant appears to have reduced dystonia severity. The UPDRS Part III
(motor scores) performed during mAIMS evaluation, indicated that dipraglurant
did not interfere with levodopa efficacy.
Patient-reported, diary data supported the objective, observer-reported mAIMS
data, with an increase in daily on-time without dyskinesia up to twice that of
placebo; i.e. dipraglurant patients had as much as 70 minutes more on-time
without dyskinesia than placebo patients. Furthermore, during Week 4, patients
reported a reduction in daily off-time of 50 minutes, suggesting an effect on
parkinsonian motor symptoms in addition to the observed reductions in LID.
Patients and clinicians tended to favor dipraglurant treatment for dyskinesia
with a higher percentage reporting improvement for the dipraglurant group, as
measured by the PGIC and CGIC.
"These data for dipraglurant are positive and we are pleased to have
demonstrated robust proof of concept," said Charlotte Keywood, MD, Chief Medical
Officer of Addex. "Both dipraglurant doses had a good safety and tolerability
profile and demonstrated efficacy. The increase in on-time without dyskinesia,
combined with the decrease in off-time observed during week 4, is encouraging,
and warrants further evaluation. It's particularly promising that the
significant reduction in dyskinesia severity on the mAIMS was mirrored by a
reduction in patient reported dyskinesia time and that both clinicians and
patients favoured dipraglurant over placebo."
A successful treatment for PD-LID would change the way Parkinson's disease is
treated, by enabling physicians to use the most effective drug for Parkinson's
disease - levodopa - earlier and more aggressively, according to market research
carried out by Datamonitor for Addex. In addition, based on robust preclinical
data, potential label expansions for dipraglurant include: PD motor symptoms
and/or non-motor symptoms, like co-morbid anxiety and depression, as well as
non-parkinsonian dystonias.
"Addex is leading the effort in developing this potential breakthrough therapy,
which could change the treatment paradigm for Parkinson's disease," said Dr.
Bharatt Chowrira, CEO of Addex. "With these promising positive data in hand, we
intend to seek a partner to progress dipraglurant to the market as rapidly as
possible."
While dipraglurant has broad potential for treating Parkinson's and other
diseases, the most direct path to market is treatment of PD-LID. No drug is
approved for PD-LID and LID has been identified by the regulatory authorities,
patient advocacy groups, such as The Michael J. Fox Foundation, and key opinion
leaders as a very important unmet medical need. The potential market opportunity
for dipraglurant in Parkinson's disease is well in excess of $1 billion,
according to Datamonitor. Potential label expansions could more than double the
peak sales potential for dipraglurant.
Dyskinesia & PD
PD is a chronic, progressive neurological disorder that affects one in 100
people over the age 60 but as young as 18. Approximately 7.5 million people
worldwide are suffering from this neurodegenerative disorder. The most commonly
administered drug to treat Parkinson's symptoms is levodopa (also called L-
dopa), which helps restore levels of dopamine, a chemical messenger in the
brain. Following prolonged use, approximately 80 percent of patients treated
with levodopa will develop uncontrollable movements, i.e. dyskinesias, a major
source of disability in their lives.
To learn about dyskinesia, listen to this podcast featuring Dr. Sherer and
produced by The Michael J. Fox Foundation for Parkinson's Research or find
additional information on PD at the Foundation's website.
mGluR5 inhibition
There is increasingly convincing evidence that mGluR5 inhibition may be a
valuable new strategy for treating Parkinson's disease. Recent clinical and
preclinical research show that mGluR5 inhibition alleviates PD-LID. Clinical and
preclinical evidence suggest that mGluR5 inhibition also may have an effect on
parkinsonian motor symptoms. mGluR5 is found in regions of the brain considered
to be key control points in the neuronal movement circuits affected by abnormal
signaling by the neurotransmitter glutamate in PD. Perturbations in glutamate
signaling (along with disruptions in dopaminergic signaling) are believed to be
an underlying cause of movement disorders like Parkinson's disease. As such,
inhibiting mGluR5 could act to re-establish normal movement via a non-
dopaminergic mechanism. Separately, preclinical findings also suggest that
mGluR5 inhibitors may be neuroprotective and may, therefore, hold potential as
disease modifying agents that can slow or prevent progression of PD. The mGluR5
inhibition mechanism also has achieved validation for other indications
including, anxiety, depression, pain and Fragile X syndrome.
A webcast and conference call will be held tomorrow at 16:00 CET (15:00
GMT/11:00 ET) tomorrow, March 22, 2012. To participate, please listen to the
webcast or call one of the following telephone numbers. RSVP is not necessary.
Dial-in numbers: +41 91 610 56 00 (Europe)
+44 203 059 58 62 (UK)
+1 866 291 4166 (USA)
The live webcast, webcast replay and transcript, will be available at
www.addextherapeutics.com.
Addex Therapeutics (www.addextherapeutics.com) discovers and develops an
emerging class of small molecule drugs, called allosteric modulators, which have
the potential to be more specific and confer significant therapeutic advantages
over conventional "orthosteric" small molecule or biological drugs. The Company
uses its proprietary discovery platform to address receptors and other proteins
that are recognized as attractive targets for modulation of important diseases
with unmet medical needs. The Company's two lead products are being investigated
in Phase II clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several
preclinical programs including: GABA-BR PAM for pain, overactive bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive
system disorders. In addition, Addex has discovery programs to identify
allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including
TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's
and Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM
for inflammation (e.g. rheumatoid arthritis) and other diseases.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addextherapeutics.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the
potential approval of its products by regulatory authorities, or regarding
potential future revenues from such products. Such forward-looking statements
reflect the current views of Addex Therapeutics regarding future events, future
economic performance or prospects, and, by their very nature, involve inherent
risks and uncertainties, both general and specific, whether known or unknown,
and/or any other factor that may materially differ from the plans, objectives,
expectations, estimates and intentions expressed or implied in such forward-
looking statements. Such may in particular cause actual results with allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB
or other therapeutic targets to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR,
FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutics targets will be approved
for sale in any market or by any regulatory authority. Nor can there be any
guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR,
FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic targets will achieve
any particular levels of revenue (if any) in the future. In particular,
management's expectations regarding allosteric modulators of mGluR2, mGluR4,
mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic targets
could be affected by, among other things, unexpected actions by our partners,
unexpected regulatory actions or delays or government regulation generally;
unexpected clinical trial results, including unexpected new clinical data and
unexpected additional analysis of existing clinical data; competition in
general; government, industry and general public pricing pressures; the
company's ability to obtain or maintain patent or other proprietary intellectual
property protection. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those anticipated, believed, estimated or expected.
Addex Therapeutics is providing the information in this press release as of this
date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise, except as may be required by applicable laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Therapeutics via Thomson Reuters ONE
[HUG#1596306]
Unternehmensinformation / Kurzprofil:
Datum: 21.03.2012 - 18:00 Uhr
Sprache: Deutsch
News-ID 127254
Anzahl Zeichen: 17920
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 279 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
